AstraZeneca Plans $200-Million Manufacturing Plant in China
AstraZeneca is investing $200 million in a new manufacturing site in China Medical City (CMC), Taizhou, Jiangsu province, China. The new site represents AstraZeneca?s largest investment in a single manufacturing facility globally.
AstraZeneca is investing $200 million in a new manufacturing site in China Medical City (CMC), Taizhou, Jiangsu province, China. The new site represents AstraZeneca’s largest investment in a single manufacturing facility globally.
The site will produce intravenous and oral solid medicines for the company’s business in China. Construction of the site is scheduled to be complete at the end of 2013.
AstraZeneca first established a presence in China in 1993 and generated more than $1 billion in revenues in that country in 2010. AstraZeneca’s other facilities and project work in China include a manufacturing and supply site in Wuxi New District, Jiangsu Province; the AstraZeneca Innovation Center China, a translational science center; an established sales and marketing operation; large-scale clinical development capabilities; and a network of collaborations with academic and medical institutions.
AstraZeneca’s plans for its new manufacturing site in China follow recent investment in emerging markets. In June 2011, AstraZeneca unveiled plans to establish a Predictive Science Center in St. Petersburg, Russia. The center will be staffed with 30 employees and focus on developing bioinformatics, data-analysis methods, software, and systems to help predict the safety and efficacy of potential new medicines. Earlier this year, the company began constructing a $150-million manufacturing facility in the Kaluga region to supply locally manufactured medicines in Russia.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
